Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.
Prohormone convertase 2 (PC2) plays an essential role in the processing of proglucagon to mature active glucagon in pancreatic alpha-cells (J Biol Chem 276:27197-27202, 2001). Mice lacking PC2 demonstrate multiple defects, including chronic mild hypoglycemia and dramatic hyperplasia of the pancreatic alpha-cells. To define the contribution of mature glucagon deficiency to the hypoglycemia and alpha-cell hyperplasia, we have attempted to correct the defects by delivery of exogenous glucagon by micro-osmotic pumps. Intraperitoneal delivery of 0.5 microg glucagon/h in PC2(-/-) mice resulted in the normalization of blood glucose concentrations. Islet remodeling through the loss of hyperplastic alpha-cells was evident by day 11 after pump implantation; by 25 days postimplantation, PC2(-/-) islets were indistinguishable from wild-type islets. These rapid changes were brought about by induction of apoptosis in the alpha-cell population. Morphological normalization of islets was also accompanied by marked downregulation of endogenous preproglucagon gene expression, but with little or no change in the level of preproinsulin gene expression. Exogenous glucagon delivery also normalized hepatic expression of the gluconeogenic enzyme PEPCK. These results demonstrate that the lack of mature glucagon in PC2(-/-) mice is responsible for the aberrant blood glucose levels, islet morphology, and gene expression, and they confirm the role of glucagon as a tonic insulin antagonist in regulating glycemia.
Webb
Gene C
GC
Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA.
Akbar
Murtaza S
MS
Zhao
Chongjian
C
Swift
Hewson H
HH
Steiner
Donald F
DF
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D001786:Blood Glucose / Q000032:analysis; D015870:Gene Expression / Q000187:drug effects; D005934:Glucagon / Q000008:administration & dosage* / Q000627:therapeutic use; D006965:Hyperplasia; D007003:Hypoglycemia / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D007515:Islets of Langerhans / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D008099:Liver / Q000503:physiopathology; D051379:Mice; D018345:Mice, Knockout / Q000235:genetics; D045706:Proprotein Convertase 2; D013381:Subtilisins / Q000172:deficiency* / Q000235:genetics
D001786:Blood Glucose; D005934:Glucagon; D013381:Subtilisins; D045706:Proprotein Convertase 2